Rongtai

Jiangsu Rongtai Biotechnology is a China-based private biotech company founded in 2017 and headquartered in Nanjing. The company focuses on biological macromolecules and related drug R&D, with an emphasis on fusion protein therapeutics for anti-inflammatory, analgesic, antitumor immunotherapy, and ophthalmic applications. In addition to internal drug discovery, Rongtai has built technical service platforms spanning recombinant protein expression, mammalian transient expression, high-throughput recombinant antibody production, antigen preparation, and customized antibody development. Its customer base appears to include universities, research institutes, and biopharma R&D companies. Publicly visible evidence suggests the company remains primarily a preclinical and platform-oriented biologics developer rather than a late-stage clinical company.